Merck recalls cholesterol drug Liptruzet (Update)

by Dennis Thompson, Healthday Reporter
Merck recalls cholesterol drug liptruzet
Packaging problem could allow air, moisture to affect drug's effectiveness, company says.

(HealthDay)—Packaging defects have prompted a recall of a combination cholesterol drug called Liptruzet, produced by Merck & Co., temporarily affecting the entire U.S. stock.

Merck said the foil pouches holding Liptruzet pills could allow air and moisture inside, potentially decreasing the drug's effectiveness.

The recall covers all four dose strengths and every batch that's gone out since Liptruzet hit the market in May.

Liptruzet combines two medications that work together to reduce "bad" cholesterol levels:

  • Atorvastatin, the generic version of the widely used cholesterol medication Lipitor, which reduces the body's natural cholesterol production, and
  • Zetia (ezetimibe), a Merck-produced drug that decreases the amount of cholesterol absorbed from food.

Cardiologists expect no health problems to result from the recall, in part because both atorvastatin and Zetia will remain available separately.

"Patients are not going to be in any harm's way just going on atorvastatin until this packaging issue gets corrected," said Dr. Kevin Marzo, chief of cardiology at Winthrop-University Hospital in Mineola, N.Y.

Marzo added that since the drug has been out for just a matter of months, it's unlikely that doctors have been prescribing it widely.

If a doctor feels a patient needs the combination treatment, then the doctor can prescribe both drugs individually and the patient can take two pills, said Dr. Deepak Bhatt, executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center, in Boston.

Patients can continue to take any Liptruzet they already have on hand, according to Merck, and should talk with their doctor before they quit taking it.

Bhatt said the real risk of this recall is that patients will hear about it and stop taking their cholesterol medication altogether.

"It should be relatively simple and even cheaper to substitute atorvastatin," Bhatt said. "Bottom line, this is something that can be addressed in a relatively straightforward way. The key is not to say, 'Well, I don't have to take anything in its place.'"

Liptruzet and Zetia each cost more than $5.50 per pill, while atorvastatin costs about a quarter per pill.

Merck said it plans to get Liptruzet back on the market as soon as possible.

More information: For more on Liptruzet, visit RxList.

add to favorites email to friend print save as pdf

Related Stories

Merck: FDA wants more studies of insomnia drug

Jul 01, 2013

Drugmaker Merck & Co. says federal regulators have ruled that they won't approve high doses of its experimental insomnia medication because of concerns about their safety.

Merck says FDA reviewing its ragweed allergy therapy

May 08, 2013

Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

Germany's Merck to buy materials supplier AZ

Dec 05, 2013

Germany's Merck KGaA has announced plans to buy AZ Electronic Materials, which supplies high-tech materials for the electronics industry, for about 1.6 billion pounds ($2.6 billion).

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

23 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

23 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments